MedPath
FDA Product

Omlonti

Product approved by U.S. Food and Drug Administration (US)

Basic Information

Omlonti

65086-002

Regulatory Information

65086-002

NDA215092

C73594

October 9, 2023

USA

These highlights do not include all the information needed to use OMLONTI safely and effectively. See full prescribing information for OMLONTI . OMLONTI (omidenepag isopropyl ophthalmic solution) 0.002%, for topical ophthalmic use Initial U.S. Approval: 2022

HUMAN PRESCRIPTION DRUG LABEL

11

Company Information

869321331

Active Ingredients

OMIDENEPAG ISOPROPYL

Quantity: 0.02 mg in 1 mL

Code: G0G0H52U6K

Class Code: ACTIB

Inactive Ingredients

TRISODIUM CITRATE DIHYDRATE

Code: B22547B95K

Class Code: IACT

CITRIC ACID MONOHYDRATE

Code: 2968PHW8QP

Class Code: IACT

POLYOXYL 35 CASTOR OIL

Code: 6D4M1DAL6O

Class Code: IACT

EDETATE DISODIUM

Code: 7FLD91C86K

Class Code: IACT

BENZALKONIUM CHLORIDE

Code: F5UM2KM3W7

Class Code: IACT

GLYCERIN

Code: PDC6A3C0OX

Class Code: IACT

SODIUM HYDROXIDE

Code: 55X04QC32I

Class Code: IACT

WATER

Code: 059QF0KO0R

Class Code: IACT

HYDROCHLORIC ACID

Code: QTT17582CB

Class Code: IACT

Active Moieties

OMIDENEPAG

Code: Z95F9F9LU4

© Copyright 2025. All Rights Reserved by MedPath